Viva Biotech and Shanghai Biomedical Fund Announce the Cooperation to Jointly Build the Medical Innovation Achievement Transformation Platform

News

}

Home / News / Company News / Company News detail

Time: 2020-12-20

Source: Viva Biotech

[Abstract]:Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D.

SHANGHAI, CHINA ------ In Dec. 16th, 2020, the Shanghai Biomedical Industry Equity Investment Fund (hereinafter referred to as "Shanghai Biomedical Fund"), which is approved by the Shanghai Municipal Government and initiated by Shanghai Industrial Investment Holdings was launched in Shanghai. Viva Biotech attended the ceremony and signed the cooperation agreement, to jointly build the Shanghai Biomedical Innovation Achievement Transformation Platform.

Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D, actively cooperate with transformation platforms, and provide all-round medical R&D support including but not limited to CRO/CDMO/CMO services, investment incubation services, site and equipment for continuous development of scientific research results.

Previous Page：Viva Biotech and AlphaMa Reached Cooperation Agreement on IntelligentDEL (iDEL) Screening Platform Next Page：Viva Biotech Enters Strategic Collaboration with Biocytogen to Accelerate Early-stage Drug Discovery

Back

Media contact: vivapr@vivabiotech.com

This site uses cookies and your privacy choices are important to us

We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.